drugset / Trial / NCT02671942
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and pharmacokinetics of different dose roflumilast in China COPD patient.
Timeline
- Start
- 2016-03
- Primary completion
- 2018-06-13
- Completion
- 2018-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Roflumilast | Small molecule | 250 ug | Oral |
| Comparator | Roflumilast | Small molecule | 375 ug | Oral |
| Comparator | Roflumilast | Small molecule | 500 ug | Oral |